MET amplification is an important acquired resistance mechanism to first- or second-generation EGFR-tyrosine kinase inhibitors (TKIs) based on T790M mutation (13), accounting for approximately 10–20% of the acquired resistance to TKIs in EGFR-mutant NSCLC (14). The gene discussed is MET; the disease is non-small cell lung carcinoma.